NEW: No-Cost Streetwise Reports Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update

TICKERS: PAT; PTOTF

Threat Detection Company's AI Division Partners with Healthcare Firm to Increase Cancer Testing Access
News Update

Source:

Patriot One Technologies reported its Xtract AI division is working with Canexia Health to increase access to cancer testing as part of the Digital Technology Supercluster COVID-19 Program project.

In a news release, threat detection and counter-terrorism solutions company Patriot One Technologies Inc. (PAT:TSX; PTOTF:OTCQX) announced that "its wholly owned subsidiary Xtract Technologies Inc. has entered into a new project contract with Canexia Health (formerly Contextual Genomics) and supported by the Digital Technology Supercluster."

The company stated that since the onset of the COVID-19 pandemic diagnosis and treatment of many health conditions has suffered as individuals have chosen to forgo healthcare hoping to reduce their coronavirus exposure. The firm pointed out that compared to the overall population, cancer patients are twice as likely to contract COVID-19 and three times as likely to die from it. The company advised that while patients endeavor to limit their virus exposure, they are delaying medical treatments and their disease may be spreading further. The firm noted that in Canada at least 100,000 surgeries including cancer tissue biopsies have been delayed or postponed since March 2020 due to COVID-19.

The firm stated that Project ACTT (Access to Cancer Testing & Treatment in Response to COVID-19) "aims to provide a liquid biopsy solution, that requires only a simple blood draw, as an alternative to surgical tissue biopsies." The company explained that this is a remotely delivered, minimally invasive DNA test that is analyzed by artificial intelligence technology to identify circulating tumor DNA in plasma. Based upon the results of the test patients are matched with targeted treatments to optimize outcomes.

The company indicated that Xtract AI's role will be to develop and apply Natural Language Processing models to aid in managing and integrating information from a mutation and cancer-type database.

The company's CEO Martin Cronin commented, "Knowing how far reaching the effects of COVID-19 are, we're delighted to be involved in another project utilizing artificial intelligence, and our team's expertise, in an effort to significantly, and hopefully positively, impact the lives of cancer patients."

The Digital Technology Supercluster is a consortium of private and public sector organizations formed to address challenges facing Canada's healthcare, manufacturing, natural resources and transportation sectors. The collaborative COVID-19 Program specifically aims to address issues created by the SARS-CoV-2 outbreak and improve the health and safety of all Canadians.

[NLINSERT]

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: Patriot One Technologies. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Patriot One Technologies, a company mentioned in this article.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.




Learn More about Streetwise Reports Live

Want to read more about Special Situations and Technology investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe